Intronic splicing of hyaluronan synthase 1 (HAS1): A biologically relevant indicator of poor outcome in multiple myeloma

Blood

Volumn 105, Issue 12, 2005, Pages 4836-4844

  Adamia, Sophia ^b   Reiman, Tony ^b   Crainie, Mary ^b   Mant, Michael J ^b   Belch, Andrew R ^b   Pilarski, Linda M ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HYALURONIC ACID;

ARTICLE; CELL MOTILITY; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HAS1 GENE; HAS1VA GENE; HAS1VB GENE; HAS1VC GENE; HUMAN; HUMAN CELL; MITOSIS; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RNA SPLICING; STOP CODON; SYNTHESIS;

EID: 18144417341     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-10-3825     Document Type: Article

References (43)

1. Bergsagel PL, Masellis Smith A, Belch AR, Pilarski LM. The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangements. Curr Top Microbiol Immunol. 1995;194:17-24.
2. Billadeau D, Quam L, Thomas W, et al. Detection and quantitation of malignant cells in the peripheral blood of multiple myeloma patients. Blood. 1992;80:1818-1824.
3. Szczepek AJ, Bergsagel PL, Axelsson L, Brown CB, Belch AR, Pilarski LM. CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements. Blood. 1997;89: 1824-1833.
4. Szczepek AJ, Seeberger K, Wizniak J, Mant MJ, Belch AR, Pilarski LM. A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction. Blood. 1998;92: 2844-2855.
5. Alaniz L, Cabrera PV, Blanco G, et al. Interaction of CD44 with different forms of hyaluronic acid. Its role in adhesion and migration of tumor cells. Cell Commun Adhes. 2002;9:117-130.
6. Masellis-Smith A, Belch AR, Mant MJ, Turley EA, Pilarski LM. Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44. Blood. 1996;87:1891-1899.
7. Pilarski LM, Szczepek AJ, Belch AR. Deficient drug transporter function of bone marrow-localized and leukemic plasma cells in multiple myeloma. Blood. 1997;90:3751-3759.
8. Turley EA, Austen L, Moore D, Hoare K. Ras-transformed cells express both CD44 and RHAMM hyaluronan receptors: only RHAMM is essential for hyaluronan-promoted locomotion. Exp Cell Res. 1993;207:277-282.
9. Turley EA, Belch AJ, Poppema S, Pilarski LM. Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes. Blood. 1993;81:446-453.
10. Dahl IM, Turesson I, Holmberg E, Lilja K. Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood. 1999;93:4144-4148.
11. Auvinen PK, Parkkinen JJ, Johansson RT, et al. Expression of hyaluronan in benign and malignant breast lesions. Int J Cancer. 1997;74:477-481.
12. Collis L, Hall C, Lange L, Ziebell M, Prestwich R, Turley EA. Rapid hyaluronan uptake is associated with enhanced motility: implications for an intracellular mode of action. FEBS Lett. 1998; 440:444-449.
13. Evanko SP, Wight TN. Intracellular localization of hyaluronan in proliferating cells. J Histochem Cytochem. 1999;47:1331-1342.
14. Majors AK, Austin RC, de la Motte CA, et al. Endoplasmic reticulum stress induces hyaluronan deposition and leukocyte adhesion. J Biol Chem. 2003;278:47223-47231.
15. Itano N, Sawai T, Yoshida M, et al. Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem. 1999; 274:25085-25092.
16. Spicer AP, McDonald JA. Characterization and molecular evolution of a vertebrate hyaluronan synthase gene family. J Biol Chem. 1998;273: 1923-1932.
17. Itano N, Sawai T, Miyaishi O, Kimata K. Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells. Cancer Res. 1999;59:2499-2504.
18. Simpson MA, Wilson CM, Furcht LT, Spicer AP, Oegema TR Jr, McCarthy JB. Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J Biol Chem. 2002;277:10050-10057.
19. Bevilacqua A, Ceriani MC, Capaccioli S, Nicolin A. Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol. 2003;195:356-372.
20. Chen CY, Shyu AB. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem Sci. 1995;20:465-470.
21. Keats JJ, Reiman T, Maxwell CA, et al. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. Blood. 2003;101:1520-1529.
22. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
23. Knudson W, Knudson CB. Assembly of a chondrocyte-like pericellular matrix on non-chondrogenic cells. Role of the cell surface hyaluronan receptors in the assembly of a pericellular matrix. J Cell Sci. 1991;99(pt2):227-235.
24. Pilarski LM, Giannakopoulos NV, Szczepek AJ, Masellis AM, Mant MJ, Belch AR. In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease. Clin Cancer Res. 2000;6:585-596.
25. Stuhlmeier KM, Pollaschek C. Glucocorticoids inhibit induced and non-induced mRNA accumulation of genes encoding hyaluronan synthases (HAS): hydrocortisone inhibits HAS1 activation by blocking the p38 mitogen-activated protein kinase signalling pathway. Rheumatology (Oxford). 2004;43:164-169.
26. Jacobson A, Brinck J, Briskin MJ, Spicer AP, Heldin P. Expression of human hyaluronan synthases in response to external stimuli. Biochem J. 2000;348(pt 1):29-35.
27. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell. 2002;2:9-15.
28. Caballero OL, de Souza SJ, Brentani RR, Simpson AJ, Alternative spliced transcripts as cancer markers. Dis Markers. 2001;17:67-75.
29. David A, Mabjeesh N, Azar I, et al. Unusual alternative splicing within the human kallikrein genes KLK2 and KLK3 gives rise to novel prostate-specific proteins. J Biol Chem. 2002;277:18084-18090.
30. Lukas J, Gao DQ, Keshmeshian M, et al. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 2001;61:3212-3219.
31. NCBI Gene Expression Omnibus, http://www.ncbi.nlm.nih.gov/projects/geo/ gds/gdsGraph.cgi?&dataset=XAJCPSHUzvRA2VaY88ZNBIRR&dataset= WSQRQRPRjhQMO_OZ_7XOLNSW$&labels= 12634p89m84p79m74p20m15p20m15p44m39p69m54p19m10p30m25p20m5p50m20p10m5p10& group=12634p89:12639p79:12644p20:12649p20:12654p44:12659p69:12674p19:12683p30: 12688p20:12703p50:12733p10:12738p10&grouplabel=tissue&gmax=8. 61434&gmin=3.51096&title=GDS422+/+32424_at&absc= 12634p5p5p5p15m5p10p5p9p5p5p10p5p10m5p10p5p5p15m10p5p10. Accessed on January 10, 2005.
32. Adamia S, Crainie M, Kriangkum J, Mant MJ, Belch AR, Pilarski LM. Abnormal expression of hyaluronan synthases in patients with Waldenstrom's macroglobulimenia. Semin Oncol. 2003; 30:165-168.
33. Itano N, Sawai T, Atsumi F, et al. Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem. 2004;279: 18679-18687.
34. Ketterling RP, Drost JB, Scaringe WA, et al. Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations. Hum Mutat. 1999;13:221-231.
35. Krawczak M, Reiss J, Cooper DN. The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences. Hum Genet. 1992; 90:41-54.
36. Mayer K, Ballhausen W, Leistner W, Roll H. Three novel types of splicing aberrations in the tuberous sclerosis TSC2 gene caused by mutations apart from splice consensus sequences. Biochim Biophys Acta. 2000;1502:495-507.
37. Sigalas I, Calvert AH, Anderson JJ, Neal DE, Lunec J. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med. 1996;2:912-917.
38. Evans SC, Viswanathan M, Grier JD, Narayana M, El-Naggar AK, Lozano G. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2. Oncogene. 2001;20:4041-4049.
39. Misra S, Ghatak S, Zoltan-Jones A, Toole BP. Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem. 2003;278:25285-25288.
40. Baumgartner G. The impact of extracellular matrix on chemoresistance of solid tumors-experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett, 1998;131:1-2.
41. Maxwell CA, Keats JJ, Crainie M, et al. RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell. 2003;14:2262-2276.
42. Crainie M, Belch AR, Mant MJ, Pilarski LM. Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants. Blood. 1999;93: 1684-1696.
43. Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Reiman T. RHAMM overexpression: a potential mechanism contributing to extensive centrosomal abnormalities in multiple myeloma. Cancer Res. 2005;65:850-860.